Form 4: Akero COO Exercises Options, Sells Shares Under 10b5-1 Plan

Akero Therapeutics' Chief Operating Officer, Jonathan Young, executed a pre-planned transaction, exercising stock options and selling an equal number of common shares.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), engaged in transactions on September 2, 2025, pursuant to a Rule 10b5-1 trading plan dated April 29, 2025.
• Young acquired 12,500 shares of Common Stock by exercising stock options at a price of $21.1 per share.
• Concurrently, Young disposed of a total of 12,500 shares of Common Stock through multiple sales transactions.
• The sales included 9,700 shares at a weighted-average price of $45.776 (ranging from $45.48 to $46.27), 2,739 shares at a weighted-average price of $47.136 (ranging from $46.54 to $47.54), and 61 shares at $47.58.
• Following these transactions, Young directly beneficially owns 197,484 shares of Common Stock.
• Young also indirectly beneficially owns 60,000 shares of Common Stock held in three irrevocable trusts for his children, though he disclaims beneficial ownership of these shares.
• The remaining derivative securities beneficially owned by Young consist of 57,482 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While an officer sold shares, it was a pre-planned transaction under a 10b5-1 plan, indicating a routine liquidity event rather than a reaction to negative news. The officer also realized a substantial profit from the option exercise, which is a positive for the individual.

Positives

• The Chief Operating Officer realized a significant profit by exercising options at $21.1 and selling shares at prices ranging from $45.776 to $47.58.
• Transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned liquidity rather than a reaction to new, undisclosed information.

Negatives

• The Chief Operating Officer reduced his direct beneficial ownership of common stock by selling the same number of shares he acquired through option exercise, which could be interpreted as a reduction in direct exposure to the company's equity.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction by a corporate officer, which is a common occurrence across all industries. It does not provide information related to broader industry trends or competitive landscape.

Related Party Transactions

• Jonathan Young's indirect beneficial ownership of 60,000 shares held in three irrevocable trusts for his children, where his spouse is the trustee. Young disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, pre-planned insider transaction for personal financial management, not indicative of a change in company fundamentals or management's confidence.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise and sell-to-cover) by a Chief Operating Officer. Such transactions, executed under a Rule 10b5-1 plan, are typically for personal financial planning or tax purposes and do not usually signal a change in the company's fundamental outlook or management's confidence. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Akero Therapeutics, AKRO, Jonathan Young, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Officer Transaction, Beneficial Ownership